Homebiotech

biotech

biotech

Revvity to acquire Human Cell Design

Jim Cornall - September 16, 2026

biotech

Engineered immune cells trial to fight colorectal cancer approved

Jim Cornall - September 16, 2026

biotech

Elix and Axcelead DDP to collaborate on targeted protein degrader discovery

Jim Cornall - September 16, 2026

biotech

Lotus Neuro launches to deliver therapies across blood-brain barrier

Jim Cornall - September 15, 2026

biotech

New peptides slip into cells to block hard-to-target proteins

Jim Cornall - June 2, 2026

biotech

Lung cancer cells switch identity to resist treatment

Jim Cornall - June 1, 2026

biotech

Could anaemia drug have potential as cancer treatment?

Jim Cornall - June 1, 2026

biotech

Base to Base biotech podcast 61: Making tumours visible, and taking on tough challenges

Jim Cornall - May 29, 2026

biotech

Paediatric pneumococcal vaccine programme advancing

Jim Cornall - May 28, 2026

biotech

FDA clearance for universal dual-target CAR-T candidate

Jim Cornall - May 28, 2026

biotech

Positive data from chronic scrotal content pain trial

Jim Cornall - May 28, 2026

biotech

Thalassaemia treatment gets EU approval

Jim Cornall - May 27, 2026

1...202122...100 Page 21 of 100

Stay Connected

- Advertisement -

spot_img

Latest Articles

biotech

Revvity to acquire Human Cell Design

Jim Cornall - September 16, 2026 0

Revvity, Inc. has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specialising in human cell models and...

Engineered immune cells trial to fight colorectal cancer approved

biotech Jim Cornall - September 16, 2026 0

Elix and Axcelead DDP to collaborate on targeted protein degrader discovery

biotech Jim Cornall - September 16, 2026 0

Lotus Neuro launches to deliver therapies across blood-brain barrier

biotech Jim Cornall - September 15, 2026 0

Antibody targeting TSLP achieves positive results in asthma study

biotech Jim Cornall - September 15, 2026 0